Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

by Raza Azra, Galili Naomi, Mulford Deborah, Smith Scott E, Brown Gail L, Steensma David P, Lyons Roger M, Boccia Ralph, Sekeres Mikkael A, Garcia-Manero Guillermo, Mesa Ruben A
Published 2012-04-01

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

by Sugimoto Yuka, Sekeres Mikkael A, Makishima Hideki, Traina Fabiola, Visconte Valeria, Jankowska Anna, Jerez Andres, Szpurka Hadrian, O'Keefe Christine L, Guinta Kathryn, Afable Manuel, Tiu Ramon, McGraw Kathy L, List Alan F, Maciejewski Jaroslaw
Published 2012-03-01